CO4950556A1 - QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM. - Google Patents
QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM.Info
- Publication number
- CO4950556A1 CO4950556A1 CO98037149A CO98037149A CO4950556A1 CO 4950556 A1 CO4950556 A1 CO 4950556A1 CO 98037149 A CO98037149 A CO 98037149A CO 98037149 A CO98037149 A CO 98037149A CO 4950556 A1 CO4950556 A1 CO 4950556A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- compositions
- contain
- ncn
- quinoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Un compuesto de la fórmula I o IIcaracterizado porque:1, m, r, s y t son 0 ó 1;n es 0, 1 ó 2;y se selecciona del grupo que consiste de CHR12 , SO2 , SO3 , CO , CO2 , O, NR13 , SO2 NR14 , CONR15 , C(NCN), C(NCN)NR16 , NR17 CO, NR18 SO2 , CONR19 NR20 , SO2 NR21 NR22 , S(O)(NR23 ), S(NR24 ) (NR25 ), o sin Y;Z se selecciona del grupo que consiste de CR12 , S, SO, SO2 , SO3 , CO, CO2 , O, NR13 , SO2 NR14 , CONR15 , NR26 NR27 , ONR28 , NR29 O, NR30 SO2 NR31 , NR32 SO2 , NR33 C(NCN), NR34 C(NCN)NR35 , NR36 CO, NR37 CONR38 , NR39 CO2 , OCONR40 , S(O)(NR41 ), S(NR42 ) NR43 ) o CHR12 ; o sin Z;R7 , R8 se seleccionan del grupo que consiste de hidrógeno halo, nitro, ciano y U-R44 ;U se selecciona del grupo que consiste de S, O, NR45 , CO, SO, SO2 , CO2 , NR46 CO2 , NR47 CONR48 , NR49 SO2 , NR50 SO2 NR51 , SO2 NR52 , NR53 CO, CONR54 , PO2 R55 y PO3 R56 o sin U;R9 , R10 , R12 , R13 , R14 , R15 , R16 , R17 , R18 , R19 , R20 , R21 , R22 , R23 , R24 , R25 ,R26 , R27 , R28 , R29 , R30 , R31 , R32 , R33 , R34 , R35 , R36 , R37 , R38 , R39 , R40 , R41 , R42 , R43 , R44 , R45 , R46 , R47 , R48 , R49 , R50 , R51 , R52 , R53 , R54 , R55 , R56 , R57 , R58 , R59 , se seleccionan del grupo que consiste de hidrógeno, alquilo inferior, arilo, heterociclo, alquilo sustituido o arilo;R11 y R44 se seleccionan del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, aralquilo, cicloalquilo, arilo,...A compound of formula I or II characterized in that: 1, m, r, s and t are 0 or 1; n is 0, 1 or 2; and is selected from the group consisting of CHR12, SO2, SO3, CO, CO2, O, NR13, SO2 NR14, CONR15, C (NCN), C (NCN) NR16, NR17 CO, NR18 SO2, CONR19 NR20, SO2 NR21 NR22, S (O) (NR23), S (NR24) (NR25), or without Y ; Z is selected from the group consisting of CR12, S, SO, SO2, SO3, CO, CO2, O, NR13, SO2 NR14, CONR15, NR26 NR27, ONR28, NR29 O, NR30 SO2 NR31, NR32 SO2, NR33 C ( NCN), NR34 C (NCN) NR35, NR36 CO, NR37 CONR38, NR39 CO2, OCONR40, S (O) (NR41), S (NR42) NR43) or CHR12; or without Z; R7, R8 are selected from the group consisting of halo, nitro, cyano and U-R44 hydrogen; U is selected from the group consisting of S, O, NR45, CO, SO, SO2, CO2, NR46 CO2, NR47 CONR48, NR49 SO2, NR50 SO2 NR51, SO2 NR52, NR53 CO, CONR54, PO2 R55 and PO3 R56 or without U; R9, R10, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 , R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46 , R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, are selected from the group consisting of hydrogen, lower alkyl, aryl, heterocycle, substituted alkyl or aryl; R11 and R44 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5159497P | 1997-07-02 | 1997-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4950556A1 true CO4950556A1 (en) | 2000-09-01 |
Family
ID=21972255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO98037149A CO4950556A1 (en) | 1997-07-02 | 1998-07-01 | QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM. |
Country Status (24)
Country | Link |
---|---|
US (2) | US6387926B1 (en) |
EP (1) | EP0994856A4 (en) |
JP (1) | JP2002507989A (en) |
KR (1) | KR100385941B1 (en) |
CN (1) | CN1261880A (en) |
AR (1) | AR016304A1 (en) |
AU (1) | AU734721B2 (en) |
BR (1) | BR9810465A (en) |
CA (1) | CA2294530A1 (en) |
CO (1) | CO4950556A1 (en) |
HU (1) | HUP0004148A3 (en) |
ID (1) | ID24076A (en) |
IL (1) | IL133470A0 (en) |
MY (1) | MY117961A (en) |
NO (1) | NO316117B1 (en) |
NZ (1) | NZ501293A (en) |
PE (1) | PE86599A1 (en) |
PL (1) | PL337697A1 (en) |
RU (1) | RU2211838C2 (en) |
TR (1) | TR199903331T2 (en) |
TW (1) | TW527355B (en) |
UY (1) | UY25074A1 (en) |
WO (1) | WO1999001434A1 (en) |
ZA (1) | ZA985778B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747023B1 (en) * | 1998-08-11 | 2004-06-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
AU754204B2 (en) * | 1998-09-01 | 2002-11-07 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6316436B1 (en) | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
CA2395772C (en) * | 1999-12-28 | 2010-09-28 | Eisai Co., Ltd. | Sulfonamide-containing heterocyclic compounds |
GB0023915D0 (en) * | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
WO2002043733A1 (en) * | 2000-11-28 | 2002-06-06 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
FR2819510B1 (en) * | 2001-01-18 | 2003-10-31 | Servier Lab | NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2819512B1 (en) * | 2001-01-18 | 2003-02-21 | Servier Lab | NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2825705B1 (en) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS |
US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
FR2835186B1 (en) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
AU2003259717A1 (en) * | 2002-08-07 | 2004-02-25 | Bristol-Myers Squibb Company | Modulators of rabggt and methods of use thereof |
FR2844273B1 (en) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS. |
ATE443048T1 (en) * | 2002-11-20 | 2009-10-15 | Japan Tobacco Inc | 4-OXOCINOLINE COMPOUNDS AND THEIR USE AS HIV INTEGRASE INHIBITORS |
WO2005007628A1 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
JP4691041B2 (en) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | GTPase inhibitors and methods of use |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
JP2007538004A (en) * | 2004-03-18 | 2007-12-27 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | How to treat synucleinopathy |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20050288298A1 (en) * | 2004-03-18 | 2005-12-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
WO2006101937A1 (en) | 2005-03-18 | 2006-09-28 | Janssen Pharmaceutica N.V. | Acylhydrazones as kinase modulators |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
EP1920048A4 (en) | 2005-07-29 | 2009-12-09 | Childrens Hosp Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
US8003624B2 (en) * | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
EP2545919A1 (en) * | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
US8383819B2 (en) * | 2006-03-06 | 2013-02-26 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
CA2650520A1 (en) * | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
AU2007321376A1 (en) * | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
CN101686982A (en) * | 2007-05-10 | 2010-03-31 | Amr科技公司 | The purposes of the tetrahydro benzo azepine that aryloxy group and heteroaryloxy replace and blocking-up norepinephrine, dopamine and 5-hydroxy tryptamine reuptake |
FR2920773B1 (en) * | 2007-09-11 | 2009-10-23 | Servier Lab | 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2009079765A1 (en) * | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
WO2010057006A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
CN103864765B (en) * | 2014-03-05 | 2016-02-10 | 天津药物研究院 | Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
ES2926579T3 (en) | 2016-05-05 | 2022-10-27 | Laurus Labs Ltd | Process for the preparation of intermediate compounds useful in the preparation of inhibitors of the Hepatitis C virus (HCV) |
WO2017213210A1 (en) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | Heterocyclic compound |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110536A (en) | 1977-04-18 | 1978-08-29 | Miles Laboratories, Inc. | Derivatives of 5-(indol-3-yl)hydantoin |
JPS5852256A (en) * | 1981-09-24 | 1983-03-28 | Nippon Nohyaku Co Ltd | Substituted or unsubstituted fatty acid amide derivative and its salt |
JPS60222479A (en) * | 1984-04-20 | 1985-11-07 | Nippon Tokushu Noyaku Seizo Kk | Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, their production and herbicide and fungicide therefrom |
US4576957A (en) | 1984-07-05 | 1986-03-18 | American Cyanamid Company | N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas |
JPS6160682A (en) * | 1984-08-30 | 1986-03-28 | Nippon Tokushu Noyaku Seizo Kk | Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, its production, herbicide, agricultural and horticultural fungicide |
JPS6168487A (en) * | 1984-09-12 | 1986-04-08 | Sumitomo Chem Co Ltd | Carbamoylazole derivative, its production, and herbicide comprising it as active ingredient |
US5017584A (en) | 1984-12-20 | 1991-05-21 | Sterling Drug Inc. | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas |
JPS61227506A (en) * | 1985-04-01 | 1986-10-09 | Nippon Tokushu Noyaku Seizo Kk | Carbamoylimidazole, intermediate and, production thereof and herbicide, agricultural and horticultural fungicide |
JPS61280408A (en) * | 1985-06-03 | 1986-12-11 | Sumitomo Chem Co Ltd | Tobacco sucker inhibitor |
JPS63270678A (en) * | 1987-04-30 | 1988-11-08 | Mitsui Petrochem Ind Ltd | Novel nitrogen-containing compound |
JP2652249B2 (en) | 1989-08-22 | 1997-09-10 | 進 根本 | Key knob cover |
US5374615A (en) | 1990-10-31 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives |
EP0485890A3 (en) * | 1990-11-16 | 1992-07-08 | Hoechst Aktiengesellschaft | Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell |
US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
US5371227A (en) | 1991-10-28 | 1994-12-06 | Synthelabo | Quinoline derivatives, process for their preparation, and their therapeutic applications |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
US5726197A (en) | 1992-11-02 | 1998-03-10 | Syntex (U.S.A.) Inc. | Isoindolinyl derivatives |
US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
CA2118985A1 (en) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
US5523317A (en) | 1993-07-05 | 1996-06-04 | Nippon Chemiphar Co., Ltd. | Method of reducing blood pressure |
US5576437A (en) | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
ES2146307T3 (en) | 1993-12-17 | 2000-08-01 | Procter & Gamble | COMPOUNDS OF 6- (2-IMIDAZOLINYLAMINE) QUINOLINE USEFUL AS 2-ALPHA ADRENOCEPTOR AGONISTS. |
HUT72440A (en) * | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
US5607939A (en) | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
TW436484B (en) | 1996-04-24 | 2001-05-28 | Dev Center Biotechnology | 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof |
WO1998002432A1 (en) | 1996-07-16 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Bicyclic compounds for controlling micturition |
UA60311C2 (en) | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
-
1998
- 1998-05-26 TW TW087108171A patent/TW527355B/en not_active IP Right Cessation
- 1998-05-29 US US09/087,179 patent/US6387926B1/en not_active Expired - Lifetime
- 1998-06-16 RU RU2000102355/04A patent/RU2211838C2/en not_active IP Right Cessation
- 1998-06-16 NZ NZ501293A patent/NZ501293A/en unknown
- 1998-06-16 EP EP98930299A patent/EP0994856A4/en not_active Withdrawn
- 1998-06-16 HU HU0004148A patent/HUP0004148A3/en unknown
- 1998-06-16 WO PCT/US1998/012549 patent/WO1999001434A1/en not_active Application Discontinuation
- 1998-06-16 AU AU79719/98A patent/AU734721B2/en not_active Ceased
- 1998-06-16 TR TR1999/03331T patent/TR199903331T2/en unknown
- 1998-06-16 CN CN98806818A patent/CN1261880A/en active Pending
- 1998-06-16 BR BR9810465-9A patent/BR9810465A/en not_active IP Right Cessation
- 1998-06-16 IL IL13347098A patent/IL133470A0/en unknown
- 1998-06-16 KR KR10-1999-7012368A patent/KR100385941B1/en not_active IP Right Cessation
- 1998-06-16 CA CA002294530A patent/CA2294530A1/en not_active Abandoned
- 1998-06-16 PL PL98337697A patent/PL337697A1/en unknown
- 1998-06-16 JP JP50718899A patent/JP2002507989A/en not_active Ceased
- 1998-06-26 PE PE1998000565A patent/PE86599A1/en not_active Application Discontinuation
- 1998-06-26 MY MYPI98002919A patent/MY117961A/en unknown
- 1998-06-30 UY UY25074A patent/UY25074A1/en not_active IP Right Cessation
- 1998-07-01 ZA ZA9805778A patent/ZA985778B/en unknown
- 1998-07-01 CO CO98037149A patent/CO4950556A1/en unknown
- 1998-07-02 AR ARP980103223A patent/AR016304A1/en unknown
-
1999
- 1999-06-16 ID IDW991728A patent/ID24076A/en unknown
- 1999-12-30 NO NO19996571A patent/NO316117B1/en unknown
-
2000
- 2000-05-05 US US09/566,396 patent/US6602883B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW527355B (en) | 2003-04-11 |
TR199903331T2 (en) | 2000-06-21 |
NO316117B1 (en) | 2003-12-15 |
ZA985778B (en) | 2000-01-20 |
ID24076A (en) | 2000-07-06 |
MY117961A (en) | 2004-08-30 |
NO996571D0 (en) | 1999-12-30 |
AR016304A1 (en) | 2001-07-04 |
NO996571L (en) | 2000-02-23 |
BR9810465A (en) | 2002-04-16 |
IL133470A0 (en) | 2001-04-30 |
KR20010014258A (en) | 2001-02-26 |
JP2002507989A (en) | 2002-03-12 |
EP0994856A4 (en) | 2000-12-06 |
HUP0004148A2 (en) | 2001-10-28 |
HUP0004148A3 (en) | 2002-09-30 |
PL337697A1 (en) | 2000-08-28 |
EP0994856A1 (en) | 2000-04-26 |
US6602883B1 (en) | 2003-08-05 |
AU7971998A (en) | 1999-01-25 |
CN1261880A (en) | 2000-08-02 |
UY25074A1 (en) | 2000-12-29 |
CA2294530A1 (en) | 1999-01-14 |
NZ501293A (en) | 2001-10-26 |
PE86599A1 (en) | 1999-11-28 |
WO1999001434A1 (en) | 1999-01-14 |
AU734721B2 (en) | 2001-06-21 |
KR100385941B1 (en) | 2003-06-09 |
US6387926B1 (en) | 2002-05-14 |
RU2211838C2 (en) | 2003-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4950556A1 (en) | QUINOLINE DERIVATIVES THAT HAVE A GROUP IMIDAZOLE AND COMPOSITIONS THAT CONTAIN THEM. | |
AR015774A1 (en) | EPOTILONE DERIVATIVES 12,13-MODIFIED AND ITS SALTS | |
AR045761A1 (en) | DERIVATIVES OF 2-PIRIDONA AS INHIBITORS OF ELASTASA DE NEUTROFILOS | |
AR030432A1 (en) | USE OF QUINAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT TO BE USED IN THE INHIBITION OF AURORA QUINASA2, RELATED COMPOUNDS, AND PHARMACEUTICAL COMPOSITION. | |
TR199903270T2 (en) | Omeprazole sodium salt. | |
AR045691A1 (en) | HETEROARILAMIDE DERIVATIVES AS P2X7 ANTAGONIST RECEIVERS AND THEIR USES | |
AR037881A1 (en) | USE OF OXINDOL DERIVATIVES | |
BG62615B1 (en) | (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase | |
NO910863L (en) | N- (4-PIPERIDINYL) (DIHYDROBENZOFURAN OR DIHYDRO-2H-BENZOPYRANE) CARBOXAMIDE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION. | |
HK1028032A1 (en) | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agent comprising the same as the active ingredient | |
NZ334125A (en) | Quinoline derivatives inhibiting the effect of growth factors such as VEGF | |
TR199900827T2 (en) | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia. | |
AR050598A2 (en) | SYNERGIC FUNGUICIDE COMPOSITION, PROCEDURE TO COMBAT HARMFUL FUNGES AND USE OF COMPOUNDS THAT INTEGRATE SUCH COMPOSITION FOR THE PREPARATION OF SUCH SYNERGIC MIXTURES | |
AR060042A1 (en) | NANOPARTICLES UNDERSTANDING A PDGF RECEPTOR THYROSINE KINASE INHIBITOR | |
PL350123A1 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
TR200000414T2 (en) | 2- (4-Aryl or heteroaryl-piperazin-1-ylmethyl) -1H-indole derivatives. | |
AR042733A1 (en) | PIRIDINE DERIVATIVES USED AS INHIBITORS OF THE NA + / CA2 + EXCHANGE MECHANISM | |
NZ502180A (en) | 6-Azauracil derivatives and their use as IL-5 inhibitors | |
DE69621651D1 (en) | AZAHEXAN DERIVATIVES AS SUBSTRATISOSTERES OF RETROVIRAL ASPARTATE PROTEASES | |
ATE248819T1 (en) | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | |
MY127758A (en) | Derivatives of homopiperidinyl substituted benzimidazole analogues | |
CO5221028A1 (en) | FUNGICIDE MIXTING THAT INCLUDES DERIVATIVES OF ETER QUINOLINE AND CARBAMATES | |
DE60000234D1 (en) | Indole compounds, their use in dyeing and making up keratin fibers, compositions containing them and dyeing processes | |
NO164836C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE NAFTYRIDINE DERIVATIVES. | |
DE50001988D1 (en) | DOLLAR g (a) - DOLLAR g (a) 'SUBSTITUTED N-ALKYL-3-ALKENYLBENZOYL-PYRAZOLE DERIVATIVES |